9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report

Termination Date

11. No Lobbying Issue Activity

INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13

12. Lobbying

13. Organizations

INCOME relating to lobbying activities
for this reporting period was:

EXPENSE relating to lobbying activities
for this reporting period were:

Less than $5,000

Less than $5,000

$5,000 or more

$

$5,000 or more

$

514,107.21

Provide a good faith estimate, rounded to the nearest
$10,000,
of all lobbying related income from the client (including all
payments to the registrant by any other entity for lobbying
activities on behalf of the client).

Digitally Signed By: Roberta Catucci, Vice President of Administration

Date

01/16/2014

LOBBYING ACTIVITY.
Select as many codes as necessary to reflect the general issue areas in which the registrant
engaged in lobbying on behalf of the client during the reporting period. Using
a separate page for each code, provide information as requested. Add additional page(s)
as needed.

15. General issue area code TAX

16. Specific lobbying issues

S.232/HR 1295 Medical Device Access and Innovation Protection Act: would appeal the medical device tax as part of the ACA; S. Con Resolution 8: an original resolution setting forth the Congressional Budget for FY2014 which would repeal the medical device tax but not identify a pay for: HR 523 Protect the Medical Innovation Act of 2013

17. House(s) of Congress and Federal agencies
Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name

Last Name

Suffix

Covered Official Position (if applicable)

New

Bobby

Franklin

Mr.

Jennifer

Dowling

Ms.

Kelly

Slone

Ms.

Emily

Baker

Ms.

Mark

Heesen

Mr.

19. Interest of each foreign entity in the specific issues listed on line 16 above
Check if None

​

LOBBYING ACTIVITY.
Select as many codes as necessary to reflect the general issue areas in which the registrant
engaged in lobbying on behalf of the client during the reporting period. Using
a separate page for each code, provide information as requested. Add additional page(s)
as needed.

18. Name of each individual who acted as a lobbyist in this issue area

First Name

Last Name

Suffix

Covered Official Position (if applicable)

New

Bobby

Franklin

Mr.

Jennifer

Dowling

Ms.

Kelly

Slone

Ms.

Emily

Baker

Ms.

Mark

Heesen

Mr.

19. Interest of each foreign entity in the specific issues listed on line 16 above
Check if None

​

LOBBYING ACTIVITY.
Select as many codes as necessary to reflect the general issue areas in which the registrant
engaged in lobbying on behalf of the client during the reporting period. Using
a separate page for each code, provide information as requested. Add additional page(s)
as needed.

15. General issue area code BAN

16. Specific lobbying issues

Implementation of Dodd-Frank Wall Street Reform and Consumer Protection Act (PL 111-203) Implementation of the JOBS Act Review of decimalization study by the SEC, required under the JOBS Act

17. House(s) of Congress and Federal agencies
Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. HOUSE OF REPRESENTATIVES, Securities & Exchange Commission (SEC)

18. Name of each individual who acted as a lobbyist in this issue area

First Name

Last Name

Suffix

Covered Official Position (if applicable)

New

Bobby

Franklin

Mr.

Jennifer

Dowling

Ms.

Kelly

Slone

Ms.

Emily

Baker

Ms.

Mark

Heesen

Mr.

19. Interest of each foreign entity in the specific issues listed on line 16 above
Check if None

​

LOBBYING ACTIVITY.
Select as many codes as necessary to reflect the general issue areas in which the registrant
engaged in lobbying on behalf of the client during the reporting period. Using
a separate page for each code, provide information as requested. Add additional page(s)
as needed.

18. Name of each individual who acted as a lobbyist in this issue area

First Name

Last Name

Suffix

Covered Official Position (if applicable)

New

Bobby

Franklin

Mr.

Jennifer

Dowling

Ms.

Kelly

Slone

Ms.

Emily

Baker

Ms.

Mark

Heesen

Mr.

19. Interest of each foreign entity in the specific issues listed on line 16 above
Check if None

​

LOBBYING ACTIVITY.
Select as many codes as necessary to reflect the general issue areas in which the registrant
engaged in lobbying on behalf of the client during the reporting period. Using
a separate page for each code, provide information as requested. Add additional page(s)
as needed.

18. Name of each individual who acted as a lobbyist in this issue area

First Name

Last Name

Suffix

Covered Official Position (if applicable)

New

Bobby

Franklin

Mr.

Jennifer

Dowling

Ms.

Kelly

Slone

Ms.

Emily

Baker

Ms.

Mark

Heesen

Mr.

19. Interest of each foreign entity in the specific issues listed on line 16 above
Check if None

​

LOBBYING ACTIVITY.
Select as many codes as necessary to reflect the general issue areas in which the registrant
engaged in lobbying on behalf of the client during the reporting period. Using
a separate page for each code, provide information as requested. Add additional page(s)
as needed.

18. Name of each individual who acted as a lobbyist in this issue area

First Name

Last Name

Suffix

Covered Official Position (if applicable)

New

Bobby

Franklin

Mr.

Jennifer

Dowling

Ms.

Kelly

Slone

Ms.

Emily

Baker

Ms.

Mark

Heesen

Mr.

19. Interest of each foreign entity in the specific issues listed on line 16 above
Check if None

​

LOBBYING ACTIVITY.
Select as many codes as necessary to reflect the general issue areas in which the registrant
engaged in lobbying on behalf of the client during the reporting period. Using
a separate page for each code, provide information as requested. Add additional page(s)
as needed.

15. General issue area code HCR

16. Specific lobbying issues

No bill #: Lobbied Congress to work the FDA to create a new approval pathway that could help expedite the development of certain drugs that address unmet medical needs, referred to as a special medical use pathway which can be used for a broad set of discussions No bill #: Lobbied Congress on the need for a transparent regulatory pathway for market-based reimbursement for advanced diagnostics. FDA Medical Mobile apps

17. House(s) of Congress and Federal agencies
Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), White House Office

18. Name of each individual who acted as a lobbyist in this issue area

First Name

Last Name

Suffix

Covered Official Position (if applicable)

New

Bobby

Franklin

Mr.

Jennifer

Dowling

Ms.

Kelly

Slone

Ms.

Emily

Baker

Ms.

Mark

Heesen

Mr.

19. Interest of each foreign entity in the specific issues listed on line 16 above
Check if None

​

LOBBYING ACTIVITY.
Select as many codes as necessary to reflect the general issue areas in which the registrant
engaged in lobbying on behalf of the client during the reporting period. Using
a separate page for each code, provide information as requested. Add additional page(s)
as needed.

15. General issue area code CPT

16. Specific lobbying issues

HR 3309, S.1720, S.1612, S.1013, 5.806 -- various patent reform bills

17. House(s) of Congress and Federal agencies
Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE

18. Name of each individual who acted as a lobbyist in this issue area

First Name

Last Name

Suffix

Covered Official Position (if applicable)

New

Bobby

Franklin

Mr.

Jennifer

Dowling

Ms.

Kelly

Slone

Ms.

Emily

Baker

Ms.

Mark

Heesen

Mr.

19. Interest of each foreign entity in the specific issues listed on line 16 above
Check if None

​

LOBBYING ACTIVITY.
Select as many codes as necessary to reflect the general issue areas in which the registrant
engaged in lobbying on behalf of the client during the reporting period. Using
a separate page for each code, provide information as requested. Add additional page(s)
as needed.